Bergen, 24 April 2007; NorDiag plans to enter the US market and has appointed Nancy Murphy to establish and manage its US-operation. -The US- market is the single largest market in the world for NorDiag`s products, and we are very pleased to employ an experienced capacity to lead the expansion in this challenging marketplace-, says CEO Mårten Wigstøl.

Murphy has her bioscience educational background from Olivet College, Wayne State University and Cleveland State University. She has more than 20 years international management experience in the biotechnology industry.

Murphy is today Director of Commercialization Molecular Diagnostics in Qiagen, and she has previously been responsible for building GenoVision`s US subsidiary. Other previous employers are Innogenetics, Murex and Robbins Scientific.

Murphy will start in her new position August 1st 2007.

Contactperson: CEO Mårten Wigstøl, mob. 911 657 75

About NorDiag ASA
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline NorDiag is listed on Oslo Stock Exchange with ticker NORD.